RaQualia PharmaTSE:4579 -2.70%57 PB Ratio is 1.51 as of Jul. 08, 2026, which is 65% below its 10-year median of 4.30. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,225 Biotechnology companies, RaQualia Pharma ranks better than 71.92% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-08), RaQualia Pharma's share price is 円468.00. RaQualia Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was 円310.81. Hence, RaQualia Pharma's PB Ratio of today is 1.51.
Good Sign:
RaQualia Pharma Inc stock PB Ratio (=1.55) is close to 1-year low of 1.48.
The historical rank and industry rank for RaQualia Pharma's PB Ratio or its related term are showing as below:
TSE:4579'
s PB Ratio Range Over the Past 10 Years
Min: 1.32 Med: 4.3 Max: 12.95
Current: 1.51
During the past 13 years, RaQualia Pharma's highest PB Ratio was 12.95. The lowest was 1.32. And the median was 4.30.
TSE:4579's PB Ratio is ranked better than 71.92% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs TSE:4579: 1.51
During the past 12 months, RaQualia Pharma's average Book Value Per Share Growth Rate was 21.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 2.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of RaQualia Pharma was 13.90% per year. The lowest was -21.90% per year. And the median was 2.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RaQualia Pharma PB Ratio Related Terms
RaQualia Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RaQualia Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
RaQualia Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RaQualia Pharma (TSE:4579) has a PB Ratio of 1.51 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RaQualia Pharma and its competitors. This is 65% below median its historical median of 4.30. Over the past decade, RaQualia Pharma's PB Ratio has ranged from 1.32 to 12.95. According to the industry distribution chart, RaQualia Pharma ranks #344 out of 1225 companies in the Biotechnology industry, placing it in the top 28.1%.
Is RaQualia Pharma's PB Ratio too high?
RaQualia Pharma's current PB Ratio of 1.51 is 65% below median its 10-year median of 4.30. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 12.95. The Biotechnology industry median PB Ratio is 2.92. RaQualia Pharma's value of 1.51 is 48.3% below this industry median. Based on the distribution chart, RaQualia Pharma ranks #344 out of 1225 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #344 out of 1225 companies for PB Ratio. This puts RaQualia Pharma in the upper half of its industry. The industry median PB Ratio is 2.92. RaQualia Pharma's value of 1.51 is 48.3% below this benchmark. Historically, RaQualia Pharma's own PB Ratio has ranged from 1.32 to 12.95 over the past decade. While the company's 10-year median is 4.30 vs. the industry median of 2.92, RaQualia Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current PB Ratio of 1.51 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current PB Ratio is 1.51, which is 65% below median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current PB Ratio is 1.51, which is 65% below median its 10-year median of 4.30 and 48.3% below the Biotechnology industry median of 2.92. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current PB Ratio is 1.51 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
PB Ratio: 1.51 (65% below median its 10-year median of 4.30)
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 48.3% below the Biotechnology median (#344 of 1225)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
